Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Proteo Inc operates as a clinical-stage drug development company that engages in the development of anti-inflammatory treatments for rare diseases with unmet needs. It develops, promotes and markets pharmaceuticals and other biotech products. The company is engaged in the development of pharmaceuticals based on the body's own tools and weapons to fight inflammatory diseases. It has obtained Orphan drug designations within the European Union for the use of Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension as well as for the treatment of esophageal cancer.
Irvine, CA, 92612